Nippon Chemiphar Is Managing To Slow Its Decline
As Company Credits Structural Reforms For Generating Operating Income
Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast.
